Literature DB >> 34362666

Vaccines for COVID-19: Where do we stand in 2021?

Ketaki Sharma1, Archana Koirala2, Katrina Nicolopoulos3, Clayton Chiu1, Nicholas Wood1, Philip N Britton4.   

Abstract

As of July 2021, over 3 billion doses of a COVID-19 vaccines have been administered globally, and there are now 19 COVID-19 vaccines approved for use in at least one country. Several of these have been shown to be highly effective both in clinical trials and real-world observational studies, some of which have included special populations of interest. A small number of countries have approved a COVID-19 vaccine for use in adolescents or children. These are laudable achievements, but the global vaccination effort has been challenged by inequitable distribution of vaccines predominantly to high income countries, with only 0.9% of people in low-income countries having received at least one dose of a COVID-19 vaccine. Addressing this inequity is of critical importance and will result in better control of SARS-CoV-2 globally. Other challenges include: the reduced protection from COVID-19 vaccines against some strains of SARS-CoV-2, necessitating the development of variant specific vaccines; and uncertainties around the duration of protection from vaccine-induced immunity. Crown
Copyright © 2021. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COVID-19; COVID-19 vaccines; SARS-CoV-2; Vaccines

Year:  2021        PMID: 34362666     DOI: 10.1016/j.prrv.2021.07.001

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  14 in total

1.  Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine.

Authors:  Zhenzhen Wang; Kristen D Popowski; Zhenhua Li; Dashuai Zhu; Blanca López de Juan Abad; Xianyun Wang; Mengrui Liu; Halle Lutz; Nicole De Naeyer; C Todd DeMarco; Thomas N Denny; Phuong-Uyen C Dinh; Ke Cheng
Journal:  Nat Biomed Eng       Date:  2022-07-04       Impact factor: 29.234

2.  Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer.

Authors:  Paulo Gabriel Siqueira; Heitor Oliveira Duarte; Márcio das Chagas Moura
Journal:  Vaccine       Date:  2022-05-19       Impact factor: 4.169

3.  Impact of Coronavirus Disease of 2019 Vaccine on Health and Physical Activities Among Physical Education Students in China.

Authors:  Rizwan Ahmed Laar; Zhengyi Zhang; Rashid Menhas; Lei Zhang; Shicheng Zhu; Xin Fan; Wei Wang; Shumin Li
Journal:  Front Public Health       Date:  2022-07-04

Review 4.  An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19).

Authors:  Armina Alagheband Bahrami; Ali Azargoonjahromi; Samin Sadraei; Aryan Aarabi; Zahra Payandeh; Masoumeh Rajabibazl
Journal:  Cell Mol Biol Lett       Date:  2022-05-13       Impact factor: 8.702

5.  A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant.

Authors:  Mengxin Zhang; Ying Liang; Dongsheng Yu; Bang Du; Weyland Cheng; Lifeng Li; Zhidan Yu; Shuying Luo; Yaodong Zhang; Huanmin Wang; Xianwei Zhang; Wancun Zhang
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

Review 6.  Care for dementia patients and caregivers amid COVID-19 pandemic.

Authors:  Avanthi Paplikar; Jayeeta Rajagopalan; Suvarna Alladi
Journal:  Cereb Circ Cogn Behav       Date:  2022-01-18

Review 7.  Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines.

Authors:  Mohammad Reza Zinatizadeh; Peyman Kheirandish Zarandi; Maryam Zinatizadeh; Mohammad Hadi Yousefi; Jaffar Amani; Nima Rezaei
Journal:  Biomed Pharmacother       Date:  2021-12-10       Impact factor: 7.419

8.  The environmental impact of mass coronavirus vaccinations: A point of view on huge COVID-19 vaccine waste across the globe during ongoing vaccine campaigns.

Authors:  Vasudha Hasija; Shilpa Patial; Pankaj Raizada; Sourbh Thakur; Pardeep Singh; Chaudhery Mustansar Hussain
Journal:  Sci Total Environ       Date:  2021-11-23       Impact factor: 10.753

9.  Computer-Based Immunoinformatic Analysis to Predict Candidate T-Cell Epitopes for SARS-CoV-2 Vaccine Design.

Authors:  Xueyin Mei; Pan Gu; Chuanlai Shen; Xue Lin; Jian Li
Journal:  Front Immunol       Date:  2022-03-30       Impact factor: 7.561

Review 10.  COVID-19 in children. II: Pathogenesis, disease spectrum and management.

Authors:  Annaleise R Howard-Jones; David P Burgner; Nigel W Crawford; Emma Goeman; Paul E Gray; Peter Hsu; Stephanie Kuek; Brendan J McMullan; Shidan Tosif; Danielle Wurzel; Asha C Bowen; Margie Danchin; Archana Koirala; Ketaki Sharma; Daniel K Yeoh; Philip N Britton
Journal:  J Paediatr Child Health       Date:  2021-10-25       Impact factor: 1.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.